| 83.69 Delayed Data As of Sep 13 |  +0.52 / +0.63%Today’s Change | 60.27 Today|||52-Week Range 99.73 | +14.79% Year-to-Date |
| What Makes Alnylam (ALNY) a New Buy Stock Sep 13 / Zacks.com - Paid Partner Content | Why Is Alnylam (ALNY) Up 2.3% Since Last Earnings Report? Sep 05 / Zacks.com - Paid Partner Content |
| Previous close | 83.17 |
| Today’s open | 83.14 |
| Day’s range | 83.04 - 85.69 |
| Volume | 862,244 |
| Average volume (3 months) | 805,000 |
| Market cap | $9.3B |
| Earnings growth (last year) | -39.67% |
| Earnings growth (this year) | -6.90% |
| Earnings growth (next 5 years) | +163.00% |
| Revenue growth (last year) | -16.69% |
| P/E ratio | NM |
| Price/Sales | 97.91 |
| Price/Book | 6.52 |
| Today’s change | Today’s % change | |
|---|---|---|
| IONSIonis Pharmaceutical... | -0.68 | -1.02% |
| SAGESAGE Therapeutics In... | -1.11 | -0.69% |
| GLPGGalapagos NV | +1.09 | +0.68% |
| MYLMylan NV | -0.55 | -2.47% |
| Next reporting date | November 6, 2019 |
| EPS forecast (this quarter) | -$2.09 |
| Annual revenue (last year) | $74.9M |
| Annual profit (last year) | -$761.5M |
| Net profit margin | -1,016.58% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director John M. Maraganore |
President Barry E. Greene |
Corporate headquarters Cambridge, Massachusetts |
